Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1439-0507.1988.tb03653.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The proteomic response of to amphotericin B (AmB) reveals the involvement of the RTA-like protein RtaA in AmB resistance.
Microlife
December 2024
Department of Molecular and Applied Microbiology, Leibniz Institute for Natural Product Research and Infection Biology, Hans Knöll Institute (HKI), Adolf-Reichwein-Str. 23, 07745 Jena, Germany.
The polyene antimycotic amphotericin B (AmB) and its liposomal formulation AmBisome belong to the treatment options of invasive aspergillosis caused by . Increasing resistance to AmB in clinical isolates of species is a growing concern, but mechanisms of AmB resistance remain unclear. In this study, we conducted a proteomic analysis of exposed to sublethal concentrations of AmB and AmBisome.
View Article and Find Full Text PDFAn immunological perspective in the treatment strategy of allergic bronchopulmonary aspergillosis.
QJM
January 2025
Flat 6 Souchay Court, 1 Clothorn Road, Manchester, M20 6BR.
Pulmonary overlap syndrome in a patient with bronchial asthma.
BMJ Case Rep
January 2025
Pulmonary, Critical Care and Sleep Medicine, ESICPGIMSR, New Delhi, Delhi, India.
Allergic bronchopulmonary aspergillosis (ABPA) is a disease of immunocompetent patients, and invasive pulmonary aspergillosis is seen in immunocompromised patients. Hence, pulmonary overlap syndrome presenting with ABPA and invasive aspergillosis is extremely rare. We report a case of well-controlled bronchial asthma who presented with acute exacerbation and hypoxaemic respiratory failure.
View Article and Find Full Text PDFRespiratory Outcomes and Aspergillus Serology Following Elexacaftor/Tezacaftor/Ivacaftor Therapy in People with Cystic Fibrosis and a History of Aspergillus fumigatus Infection.
Lung
January 2025
Mother and Child Department, Cystic Fibrosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Purpose: The study evaluated the effects of elexacaftor/tezacaftor/ivacaftor (ETI) therapy in people with cystic fibrosis (pwCF) and a clinical history of Aspergillus fumigatus (AF) infection.
Methods: This prospective cohort study included pwCF who initiated ETI therapy and had received antifungal treatment in the preceding five years due to allergic bronchopulmonary aspergillosis (ABPA group) or other AF-related clinical manifestations (AF group). A control group of pwCF with no prior respiratory cultures positive for AF was also included.
Hemophagocytic Lymphohistiocytosis in a Kidney Transplant Recipient: Case Report.
Transplant Proc
January 2025
Nephrology, Hospital Universitario Donostia, San Sebastián, España.
Hemophagocytic lymphohistiocytosis is a potentially fatal multisystemic inflammatory syndrome that is better understood in the pediatric population. Consequently, the diagnostic criteria for adults still derives from studies conducted in the pediatric population. Several genetic mutations and secondary causes, including infections, autoimmunity, and malignancy, have been reported as significant actors in this condition, especially in adults.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!